Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of “Hold” by Analysts

Agenus Inc. (NASDAQ:AGEN) has been assigned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $14.50.

A number of equities research analysts have recently issued reports on AGEN shares. HC Wainwright reissued a “buy” rating on shares of Agenus in a report on Monday, October 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th.

Agenus Trading Down 9.2%

Shares of AGEN stock opened at $3.34 on Friday. The firm’s 50 day moving average is $3.90 and its 200 day moving average is $4.43. The stock has a market capitalization of $113.59 million, a P/E ratio of -1.57 and a beta of 1.58. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported $1.94 EPS for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The firm had revenue of $30.24 million during the quarter, compared to analysts’ expectations of $80.39 million. On average, equities analysts predict that Agenus will post -12.55 EPS for the current year.

Institutional Investors Weigh In On Agenus

Hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. purchased a new stake in Agenus during the first quarter valued at about $88,000. AQR Capital Management LLC boosted its holdings in Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 427,604 shares during the period. Acadian Asset Management LLC purchased a new stake in Agenus during the 1st quarter valued at about $58,000. Strs Ohio bought a new position in Agenus during the 1st quarter worth approximately $214,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Agenus in the 2nd quarter worth approximately $85,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.